Bliss GVS Pharma Ltd approves unaudited Q2 and H1 FY27 results for the period ended September 30, 2026
- Results cover both standalone and consolidated financials.
- Auditors’ Limited Review Report was also approved.
Bliss GVS Pharma Board Meeting Highlights
This is an automated summary of a public document. Always check the original before relying on it.